Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Participants included 213 males aged ≥ 12 years with severe hemophilia A or B ... Hema Biologics/LFB SA, Novo Nordisk, Octapharma AG, Pfizer, Sanofi, Spark Therapeutics, and Takeda; as well ...

Bagsværd, Denmark-based Novo Nordisk is a global healthcare company ... The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

The expansion of the industrial plant of Novo Nordisk aims to increase the production capacity of injectable treatments for ...